Single-agent anti-PD-1 balstilimab or in combination with anti-CTLA-4 zalifrelimab for recurrent/metastatic (R/M) cervical cancer (CC): Preliminary results of two independent phase II trials

D. M. O'Malley, A. Oaknin, B. J. Monk, A. Leary, F. Selle, J. Alexandre, L. M. Randall, C. Rojas, M. Neffa, A. Kryzhanivska, L. Gladieff, D. Berton, T. Meniawy, I. Lugowska, I. Bondarenko, K. N. Moore, W. I. Ortuzar Feliu, M. Ancukiewicz, I. Shapiro, I. L. Ray-Coquard

Research output: Contribution to journalAbstract/Meeting Abstractpeer-review

29 Citations (Web of Science)
Original languageEnglish
Pages (from-to)S1164-S1165
Number of pages2
JournalAnnals of Oncology
Volume31
DOIs
Publication statusPublished - Sept 2020
EventESMO Virtual Congress 2020 - , Virtual
Duration: 19 Sept 202021 Sept 2020

Cite this